Fig. 1.

Cav-1 transcriptionally represses FST. In primary cav-1 KO MC, FST expression was increased at both the transcript level (n = 12, *p < 0.05) (a) and protein level (n = 9, *p < 0.05) (b). c Immunoblotting after FST downregulation with siRNA showed the specificity of the FST antibody in cav-1 KO MC (n = 2). d FST was elevated in the kidneys of cav-1 KO mice (n = 4 mice, *p < 0.05, representative micrographs shown). e MC were treated with the transcriptional inhibitor actinomycin D (1 μg/ml), and FST transcript assessed at the indicated times. FST mRNA stability did not differ between cav-1 WT and KO MC (n = 5). f Cav-1 WT and KO MC were treated with the translational inhibitor cycloheximide (10 μg/ml), and FST protein assessed at the indicated times. FST protein stability was not altered by cav-1 KO (n = 3)